IRCT20161210031316N2 IRCT 2018-02-13 Arak University of Medical Sciences Nonalcoholic fatty liver treatment Therapeutic effects of losartan in nonalcoholic steatohepatitis 2016-11-01 anticipated 42 Complete https://irct.ir/trial/24665 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: In a simple random method, using a flip the coin, they enter one of the groups or control, Blinding description: For both groups, placebo capsules with similar characteristics will be used, and none of the patients will be aware of the two groups of received drugs, and the two groups will be followed up and examined and the investigator will be aware of the patient's drug intake. 3 NASH. Intervention 1: Control group: Placebo for 6 month. Intervention 2: Intervention group 1: Losartan (abidi: lostar) 25 mg daily for 6 month. Yes - There is a plan to make this available What will be shared: In this study, after unidentification, all the study data, including demographic information, paraclinical outcomes and the results of the study, including the results of tests and paraclinic and the treatment complications, will be published. When: Concurrent with the publication of the study results To whom: Researchers in Medical Sciences Conditions: For further research, researchers will be able to access data from the research vice president. Where to obtain: Supervisor How to obtain: First, you must contact the supervisor by email, and then the supervisor handles the request with the deputy investigator and, if approved, provides the supervisor or documentary master with the requester. Comments: